Lymphatic filariasis caused mainly by infection from Wuchereria bancrofti and Brugia malayi remains as the major cause of clinical morbidity in tropical and subtropical countries. Development of vaccine against filarial infection can act as additional measure to the existing therapeutic and vector control methods in the control of this disease. The main hurdles in the development of anti-filarial vaccine are the strict primate specificity of Wuchereria bancrofti,
Lymphatic filariasis is characterized by a wide spectrum of clinical manifestations in individualsof endemic region, with signs and symptoms often differing from one endemic area to another (3, 4) . The type of clinical presentation is often the outcome of a complex interaction of several factors and processes including the human immune response, the varying stages of parasite and their molecules and the environment. The spectrum of manifestations include (a)asymptomatic microfilaraemia (having mf in circulation but without any clinical manifestations); (b) acute filariasis (which generally includes fever with chills, rigor, pain and swelling of upper and lower limbs associated with lymphangitis and lymphadenitis and genital manifestations like epididymoorchitis and funiculitis in male); (c) chronic manifestations (that mainly include lymphoedema, hydrocel e and elephantiasis) and d) occult filariasis (with out mf and having atypical manifestations like tropical pulmonary eosinophilia (TPE), arthritis, etc.,). Apart from these, any endemic population comprises of a certain group, often described as 'endemic normal' having no detectable mf and without any symptoms. It is possible that some of these people have sub-threshold microfilariae or sub-clinical infection (5) and some may be 'truely' immune to the parasite.
IMMUNOLOGICAL APPROACH TO CONTROL FILARIASIS PROTECTIVE IMMUNITY IN FILARIASIS A) Acquired protective immunity
Immunity to filarial infection has generally been defined as the absence of evidence of infection or sign of disease in an individual who is exposed to continuing parasite transmission. Although the proof of such sterile immunity against filarial infection is not conclusive, it seems that some level of naturally acquired protection does exist (6) . This is evident from certain immunological correlates found in the filarial 'endemic normal' group. Both cellular and humoral responses to filarial antigens were found to be higher in this group compared to microfilaraemic cases with or without symptoms (8, 9) . This heterogenous group with the absence of filarial infection or the presence of infection below the detection threshold is equally exposed to the parasite as the other infected groups. Such 'putatively immune' sub population in a filarial endemic area provides an indirect evidence of presence of naturally acquired protective immunity in humans against filarial infection (10, 11) . The existence of this putatively immune group presents a strategy for the identification of antigen(s) that might provide host protection upon prophylactic immunization (10) . The antigens preferentially recognized by this group and not by microfilaraemic cases can be considered as promising candidates for prophylactic use.
A rational immunological approach in the control of lymphatic filariasis has been a chalrenging problem due to the limited understanding of biology and immunobiology of these unique parasites. The other main problems that hindered the development of filarial vaccine are the strict primate specificity of W. bancrofti, the paucity of parasite material for identification of protective antigens and the diversity of clinical manifestations and their associated complex immune responses. There has been no sufficient data available on mechanisms of hostparasite interactions and on the phenomena responsible for protective immunity. Inspite of these limitations, the varied strategies being employed for the development of filarial vaccine have resulted in a significant progress in this direction in the recent years (6,7).
B) Concomitant immunity in filariasis
Immunity, which protects the already infected individuals from super infection with further waves of parasites, is termed as 'concomitant immunity'. Here the protective immune response is specifically targeted against infective larvae while the already residing fecund adult worms remain functionally intact. In an immuno-epidemiological study in bancroftian filarial endemic area of Papua New Guinea (PNG), Day eto al. (12) showed that there were no any 'worm-free' endemic normals in that population with intense filarial transmission. Based on circulating levels of phosphoryl-choline containing antigen (considered as a marker of active infection) it has been suggested that amicrofilaraemic individuals are likely to have same adult worm burden as low microfilaraemic cases and their status of being amicrofilaraemic is possibly due to concomitant immunity.
In longitudinal studies on filarial infection dynamics in PNG (12) and Pondicherry, India (13), it was observed that the rate of gain of infection reached peak at the age of around 20 years and thereafter remained constant or reduced. These vital field data support the existence of concomitant immunity directed against early larval stage acquired by already infected adults with increasing exposure to infection.
The findings on the 'concomitant immunity' in humans can be correlated with observations in experimental animals where it has been shown that the resistance to filarial infection can be induced followed by repeated inoculations with infective larvae. Administration of multiple doses of varying or similar numbered infective larvae called as 'trickle infections' generally induces strong resistance against different filarial parasites in animals. After trickle infections the challenge larvae get killed leading to eventual reduction or total clearance of adult worms. Such experimental induction of concomitant immunity was demonstrated in Brugia pahangi infected cats (14, 15) , Acanthocheilonema viteae infected hamsters and jirds (16) and W. bancrofti infected mice (17) . These findings in epidemiological and laboratory based research on the development of concomitant immunity suggest that infective larval antigens may be of paramount importance in induction of acquired immunity to filarial infection (11) . The fact that such protective immunity against early larval stages can develop inspite of the existence of immunological tolerance to other stages (adult and/or mf) suggests that the antilarval immunity is stage specific and different from immunity against other stages of parasite (18) . Induction of protective immunity against infective larval antigens may not be pathogenic and this implies that infective larval antigens are safe protective immunogens to look for as candidate vaccines for filariasis.
VACCINE DEVELOPMENT STUDIES IN LYMPHATIC FILARIASIS A) Animal models as aids in vaccine research:
There is no established and convenient animal model for the major lymphatic filarial parasite W. bancrofti. Attempts to obtain full development of W. bancrofti even in congenitally athymic (nude) mice and immune suppressed gerbils were not successful (19) . W. bancrofti will only reach reproductive immunity in primates i.e. leaf monkeys (20) . As such modeling of lymphatic filariasis is complicated by the diversity of infection in natural host, human. No single inbred species of laboratory animal mimics such a spectrum of susceptibilities and antipodal immunological correlates (21) for which not only environmental (22) but also genetic causes (23) have been implicated. Hence natural mammalian hosts for non-human filarial parasites (e.g. dog for Dirofilaria immits or cat for B. pahangi and A. viteae in jirds) or surrogate hosts with varying permissiveness like those of fully permissive (e.g. jirds, cats, nude mice for Brugia), semi permissive (BALB/c mice) and non-permissive have been explored to identify the protective immunogens and study the mechanisms involved. In these studies animals are immunized with filarial parasites or their antigens and the immune response generated is analyzed for anti-parasite effects. The sera collected from immune animals are tested in vitro to induce antibody-dependent cellmediated cytotoxicity (ADCC) against the parasite in the presence of effector cells. Implantation in ir,~munized animals of micropore chambers constructed of inert plexiglass rings, sealed with nucleopore membranes and loaded with larval parasites is another useful technique to evaluate the acquired immunity. The recovery of adult Worms or L 4 larvae from immunized animals followed by challenge infective larval infections can provide information on the protective effect of the immunogen.
B) Immunoprophylactic studies using whole parasite
In the early experiments, live irradiated third stage (infective) larvae or naive larvae have been used to induce high level of protective immunity in several animal models. The first such attempt was made in 1969 by Wong et. al. (24) using sub-periodic B ma!ayi in monkeys. Since then successful results using irradiated L3 larvae as vaccines have been reported in many host parasite systems, including B. pahangi in dogs (25) , cats (26) , jirds (27) and mice (28) , Brugia.malayi in jirds (29) and mice (30, 31 ) and Litomosoides carini in rats (32) . Repeated exposure to infective larvae followed by termination of infections using anti-filarial drugs has also been shown to effectively stimulate the host immune system and induce protective immunity against challenge infections (33).
C) Immunoprophylactic studies using parasite antigens
Several types of crude and purified filarial antigens have been explored as protective immunogens. These include adult or larval extracts, antigens on parasite surface, excretory-secretory (ES) products and functional molecules (e.g. enzymes) essential for the growth and development of parasite in the host. The parasite antigens preferentially recognized by putatively immune endemic normals and not by infected microfilaraemic cases have also been tested to induce protection in experimental animals.
Immunization of animals with microfilarial or adult worm extracts (34, 35) and infective larval antigens (36, 37) has been shown to induce resistance against infective larvae. Immunization of jirds with a water soluble extract of B. malayi mf enhanced the host's ability to eliminate adult worms and blood-borne mf (38) . In earlier studies in our laboratory B. malayi mf and infective larvae ES antigens have been shown to induce ADCC reaction both in vitro and in situ (micropore chamber technique) against mf and L3 larval stages of the parasite (39).
In another report from this laboratory two purified filarial antigens i.e. a 120 kDa Bm A-2 of B. malayi adult worms and a 43 kDa circulating filarial antigen fraction-2 (CFA-2) of microfilaraemic plasma were found to be highly reactive with endemic normal group (40) . Both these antigens were further explored for their immunoprophylactic activity against B.
malayi infection in jird model. Sera collected from Bm A-2 immunized jirds induced a significant level of protection against mfand L3 larvae in in vitroADCC and in situ micropore chamber methods (41) . Immunization of jirds with BmA-2 antigen resulted in 88% reduction in the development of parasite to adult stage (Fig. 1) . Passive transfer of immune sera from jirds immunized with BmA-2 to naivejirds resulted in 71% reduction in adult worm recovery as observed 90 days after challenge infection with B. malayi. On the other hand the passive transfer of non-adherent spleen cells from immune jirds did not show any significant effect on the development of parasite (Fig2) suggesting importance of humoral immunity in protection. Antibody dependent cellular cytotoxicity using chronic filarial serum has been demonstrated earlier to explain amicrofilaraemia in clinical cases (42) . (47) . Using the cloned B malayi paramyosin for immunization in jirds 43% reduction in adult worm recovery was observed (48) . Recently the same group used plasmid DNA vaccine encoding paramyosin protein in mice and jirds and noted that while strong immune response was generated in the immunized animals, there was no fall in adult worm recovery (49) .
O
In another recent communication by Peralta et. at. (50) , three recombinant fiiarial antigens (parts of filarial heat shock protein, myosin and a-type IV collagen) were identified by screening expression libraries for their differential recognition by endemic normals and microfilaraemic cases. Reporting that none of these immunogens provided protection in susceptible host jird, the investigators aptly suggest REFERENCES that their 'negative' data is consistent with Walkman's conjecture that highly immunogenic parasite antigens may not be appropriate candidates for prophylactic immunization.
Most of the studies reviewed here targeted the infective larvae for immunological destruction based on the available evidence that the immune responses to L3 or L4 larval antigens are unlikely to be pathogenic. Vaccine with L3 or L4 larval antigens is expected to be effective in nafve individuals as well as currently infected cases as an adjunct along with anti-filarial drug therapy. An alternative strategy would be to develop a 'transmission blocking vaccine' by targeting mf stage for immunological clearance. There are indications that antibodies against mf components participate in the clearance of mf in experimental animals and presumably in human (38,39&45 ). An 'anti-pathology vaccine' may be indicated for the individuals with current infection to prevent the possible development of disease manifestations and an 'immuno-therapeutic vaccine' for the infected individuals where anti-filarial drugs are not effective. Presumably such an intervention will be aimed to sterilize or destroy the adult worms and prevent the generation of disease causing 'agents'.
As more information is being generated on the immunity to filarial infection, varying strategies employed have helped to identify, variety of protective antigens in filariasis. The hurdles that have been over come so far in this area should stimulate more focussed research leading to better prospects to develop a filarial vaccine in future.
